A Step-By-Step Approach To Digitalizing Biopharma Manufacturing: Part I

By Shawn Opatka, Vice President & GM Life Sciences at Honeywell

Digital transformation offers tangible advantages in terms of time, cost, and efficiency. However, adopting new technology and altering established processes and procedures may introduce potential disruptions to operations.

This perceived risk is particularly significant in the context of biopharmaceutical manufacturing operations, where the expectation is to consistently produce flawless product batches. Such organizations cannot afford errors as their teams adapt to a digital learning curve. The mere anticipation of potential risks can lead some organizations to postpone digital upgrades, depriving manufacturers of the operational benefits that digitalization can provide.

There is no reason to delay this transition. Learn about a popular way to digitalize high-risk environments that can be achieved easily in biopharma manufacturing.